Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

C-Peptide

Glucose and Diabetes

Connecting peptideC-PEPC peptide

Review status

Currently under review

Pending specialist review and validation.

What it shows

C-peptide is a small protein that is released into your bloodstream at the same time and in the same amount as the insulin your pancreas makes. This test measures the C-peptide in your blood to show how much of your own insulin your body is producing. Injected insulin does not contain C-peptide, so the result reflects only your natural insulin production.

Your care team may order this test to evaluate how well the insulin-producing beta cells in your pancreas are working. It can be collected while fasting or after a stimulation procedure, depending on the question being asked.

Why it matters

C-peptide helps distinguish reduced insulin production from insulin resistance. It is often used when figuring out the type of diabetes, monitoring remaining beta cell function over time, and guiding decisions about treatments that support or replace insulin. It can also be useful after pancreas surgery or in long-standing diabetes to assess remaining function.

The test is also used when investigating low blood sugar to tell whether insulin is coming from your body or from an outside source. Doctors may use it when evaluating possible insulin-producing tumors, medication effects, or other endocrine conditions that affect insulin secretion.

Understanding your results

A lower result usually suggests your pancreas is making little insulin, which can be seen in conditions that damage beta cells or after pancreatic surgery. A higher result may suggest your body is making a lot of insulin, as can occur with insulin resistance or with certain tumors or medications. Kidney problems can increase levels because C-peptide is cleared through the kidneys, and eating before the test can raise levels temporarily.

Your result is interpreted together with your symptoms, blood glucose, timing of your last meal, and any stimulation or suppression testing. If the result does not match how you feel or your glucose readings, your clinician may repeat the test, check related tests such as insulin, glucose, and antibodies, review medications, or evaluate kidney function.

Reference ranges

0.41.47 nmol/L
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact C-Peptide

  • Fasting and timing

    Eating shortly before the blood draw can raise C-peptide. Follow your lab’s instructions about fasting or timed stimulation tests so results are interpreted correctly.

  • Kidney function

    C-peptide is cleared by the kidneys. Reduced kidney function can increase levels independent of insulin production, affecting interpretation.

  • Diabetes medications

    Injected insulin does not contain C-peptide, while drugs that stimulate the pancreas (for example, sulfonylureas) can raise it. Tell your clinician what you take and when you took it.

  • Acute glucose changes

    Recent hypoglycemia may suppress secretion, while high glucose can stimulate it. Pair the result with a glucose measurement taken at the same time.

  • Assay interferences

    High-dose biotin supplements and certain antibodies can interfere with some immunoassays and distort results. Avoid biotin before testing if advised.

  • Pancreatic disease or surgery

    Chronic pancreatitis, cystic fibrosis–related diabetes, or partial/total pancreatectomy can lower C-peptide by reducing beta cell mass.

2026

References

  1. McGill University Health Centre. (2015, September 14). C-Peptide (Task CD 695276). Laboratory reference ranges.
  2. American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Suppl 1), S1–SXX.
  3. Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009). Evaluation and management of adult hypoglycemic disorders: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 94(3), 709–728.